Spinoff Redvax sold to Pfizer
Redbiotec has successfully developed a CMV vaccine program based on its rePAX® technology. This program was sold to Pfizer. See Pfizer press release, January 5 2014. Pfizer press release.
“Through the acquisition of the Redvax innovative CMV vaccine platform and expertise we will seek to develop a vaccine to prevent a difficult disease that can have a devastating and lifelong impact on young children,” said Kathrin U. Jansen, a senior vice president of Pfizer.
See also investor statement Redalpine blog.
Herpes and Influenza vaccines (update Feb 2016)
Redbiotec has generated a library of novel antigens for herpes simplex virus (HSV-2). The antigens are currently being tested with human blood samples for their potential as vaccine candidates.
Redbiotec is the commercial leader of an EU-funded program with the goal to develop a broadly protective Influenza vaccine.
Beyond its vaccine activities Redbiotec is exploring the broadening of its technology platform (materials science, microorganisms engineering)